flecainide has been researched along with Genetic Predisposition in 12 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 7.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| " Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse." | 5.48 | Long-term flecainide therapy in type 3 long QT syndrome. ( Benhorin, J; Chorin, E; Flint, N; Medina, A; Taub, R; Viskin, S, 2018) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 3.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "The index case was clinically diagnosed with Brugada syndrome after flecainide test." | 3.80 | Brugada syndrome and p.E61X_RANGRF. ( Allegue, C; Berne, P; Brugada, J; Brugada, R; Campuzano, O; Iglesias, A; Selga, E, 2014) |
| " Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse." | 1.48 | Long-term flecainide therapy in type 3 long QT syndrome. ( Benhorin, J; Chorin, E; Flint, N; Medina, A; Taub, R; Viskin, S, 2018) |
| "Fibrosis was triggered by transforming growth factor β (TGF-β) pathway activation." | 1.46 | Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease. ( Baró, I; Cerpa, CO; Charpentier, F; Colledge, WH; Derangeon, M; Girardeau, A; Grace, AA; Huang, CLH; Jagu, B; Montnach, J; Patin, J; Toumaniantz, G, 2017) |
| "Catecholaminergic polymorphic ventricular tachycardia was diagnosed with the aid of an implantable loop recorder." | 1.39 | A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. ( Anastasakis, A; Kotsaka, X; Luria, D; Mantziari, L; Paraskevaidis, S; Styliadis, IH; Vassilikos, V, 2013) |
| "Mutations in pkp2 are detected in arrhythmogenic right ventricular cardiomyopathy (ARVC)." | 1.38 | Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. ( Birchmeier, W; Cerrone, M; Chkourko, H; Delmar, M; Hund, T; Liang, FX; Lin, X; Mohler, P; Noorman, M; van der Nagel, R; van Rijen, HV; van Veen, TA, 2012) |
| "Flecainide was used in two patients for LQT-3 diagnosis and therapeutic treatment of AF." | 1.35 | A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. ( Benito, B; Berruezo, A; Brugada, J; Brugada, P; Brugada, R; Cinca, J; Freixa, X; Lizotte, E; Mont, L; Perich, RM; Tolosana, JM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Nozaki, Y | 1 |
| Kato, Y | 1 |
| Uike, K | 1 |
| Yamamura, K | 1 |
| Kikuchi, M | 1 |
| Yasuda, M | 1 |
| Ohno, S | 1 |
| Horie, M | 1 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Horigome, H | 1 |
| Derangeon, M | 1 |
| Montnach, J | 1 |
| Cerpa, CO | 1 |
| Jagu, B | 1 |
| Patin, J | 1 |
| Toumaniantz, G | 1 |
| Girardeau, A | 1 |
| Huang, CLH | 1 |
| Colledge, WH | 1 |
| Grace, AA | 1 |
| Baró, I | 1 |
| Charpentier, F | 1 |
| Chorin, E | 1 |
| Taub, R | 1 |
| Medina, A | 1 |
| Flint, N | 1 |
| Viskin, S | 1 |
| Benhorin, J | 1 |
| Pablo Flórez, J | 1 |
| García, D | 1 |
| Valverde, I | 1 |
| Rubín, J | 1 |
| Pérez, D | 1 |
| González-Vasserot, M | 1 |
| Reguero, J | 1 |
| María de la Hera, J | 1 |
| Avanzas, P | 1 |
| Gómez, J | 1 |
| Coto, E | 1 |
| Morís, C | 1 |
| Calvo, D | 1 |
| Campuzano, O | 1 |
| Berne, P | 1 |
| Selga, E | 1 |
| Allegue, C | 1 |
| Iglesias, A | 1 |
| Brugada, J | 2 |
| Brugada, R | 2 |
| Mantziari, L | 1 |
| Vassilikos, V | 1 |
| Anastasakis, A | 1 |
| Kotsaka, X | 1 |
| Paraskevaidis, S | 1 |
| Styliadis, IH | 1 |
| Luria, D | 1 |
| Benito, B | 1 |
| Perich, RM | 1 |
| Lizotte, E | 1 |
| Cinca, J | 1 |
| Mont, L | 1 |
| Berruezo, A | 1 |
| Tolosana, JM | 1 |
| Freixa, X | 1 |
| Brugada, P | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Ontiveros, G | 1 |
| Caceres, G | 1 |
| Desai, M | 1 |
| Burashnikov, E | 1 |
| Scaglione, J | 1 |
| Antzelevitch, C | 1 |
| Cerrone, M | 1 |
| Noorman, M | 1 |
| Lin, X | 1 |
| Chkourko, H | 1 |
| Liang, FX | 1 |
| van der Nagel, R | 1 |
| Hund, T | 1 |
| Birchmeier, W | 1 |
| Mohler, P | 1 |
| van Veen, TA | 1 |
| van Rijen, HV | 1 |
| Delmar, M | 1 |
| Bökenkamp, R | 1 |
| Wilde, AA | 1 |
| Schalij, MJ | 1 |
| Blom, NA | 1 |
| Lehtonen, A | 1 |
| Fodstad, H | 1 |
| Laitinen-Forsblom, P | 1 |
| Toivonen, L | 1 |
| Kontula, K | 1 |
| Swan, H | 1 |
| Kaufman, ES | 1 |
1 review available for flecainide and Genetic Predisposition
| Article | Year |
|---|---|
Quinidine in short QT syndrome: an old drug for a new disease.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 2007 |
11 other studies available for flecainide and Genetic Predisposition
| Article | Year |
|---|---|
Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Signaling; Child; Child, Preschool; Dea | 2020 |
Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease.
Topics: Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzamides; Cardiomyopathies; Co | 2017 |
Long-term flecainide therapy in type 3 long QT syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Conduction System Disease; Chil | 2018 |
Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; False Negative Reactions; Fema | 2018 |
Brugada syndrome and p.E61X_RANGRF.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Brugada Syndrome; Child; Codon, Nonsense; DNA Mutational Analys | 2014 |
A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Flecainide; Follow-Up Studi | 2013 |
A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Child, Preschool; Female; Flecainid | 2008 |
Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
Topics: Amino Acid Sequence; Amino Acid Substitution; Andersen Syndrome; Arrhythmias, Cardiac; Base Sequence | 2011 |
Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Dise | 2012 |
Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Child; Child, Preschool; Defibrillators, Implantable; Fem | 2007 |
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiog | 2007 |